What it's for (Indications)
- Tramadol hydrochloride and paracetamol combination is indicated for the short-term management of moderate to severe acute pain.
- This fixed-dose combination provides synergistic analgesic effects by combining two distinct mechanisms of action: tramadol's central opioid agonism and inhibition of norepinephrine and serotonin reuptake, and paracetamol's central analgesic and antipyretic properties.
- The clinical utility of this combination is primarily observed in situations where the pain is not adequately managed by non-opioid analgesics alone, and the benefit of opioid use is considered to outweigh the risks.
- It is not intended for long-term chronic pain management due to the opioid component and associated risks of dependence and tolerance.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults and adolescents 12 years and older, the recommended initial dose is two tablets (37.5 mg tramadol / 325 mg paracetamol per tablet). Subsequent doses can be taken every 4 to 6 hours as needed, but should not exceed eight tablets (equivalent to 300 mg tramadol and 2600 mg paracetamol) within a 24-hour period. Dosage adjustments may be necessary in patients with renal impairment (creatinine clearance <30 mL/min), where the dosing interval should be extended to not exceed two tablets every 12 hours. In patients with hepatic impairment, careful consideration and dose reduction or increased dosing intervals are required due to potential accumulation of both drugs and their metabolites. Geriatric patients (over 65 years) should also be monitored closely, and dose adjustments may be warranted based on renal and hepatic function. The lowest effective dose for the shortest duration consistent with individual patient treatment goals should always be used. |
Safety & Warnings
Common Side Effects
- Common adverse reactions reported with tramadol/paracetamol include nausea, dizziness, somnolence, constipation, headache, vomiting, diarrhea, dry mouth, dyspepsia, and pruritus.
- More serious but less common adverse effects may include seizures, serotonin syndrome (especially with concomitant serotonergic agents), respiratory depression, anaphylaxis, severe skin reactions (e.
- g.
- , Stevens-Johnson syndrome, toxic epidermal necrolysis), and hepatotoxicity (primarily due to paracetamol overdose).
- Cardiovascular effects such as orthostatic hypotension, syncope, and palpitations can occur.
- Psychiatric effects like anxiety, confusion, hallucinations, and mood alterations have also been observed.
- Patients should be counselled on recognizing and reporting any concerning symptoms promptly.
Serious Warnings
- Black Box Warning: BLACK BOX WARNING: RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and CYTOCHROME P450 2D6 ULTRA-RAPID METABOLISM. 1. **Concomitant Use with Benzodiazepines or Other CNS Depressants:** Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Prescribe concomitant medications with caution and only for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation. 2. **Addiction, Abuse, and Misuse:** Tramadol/paracetamol exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing and monitor all patients regularly for the development of these behaviors and conditions. 3. **Life-Threatening Respiratory Depression:** Serious, life-threatening, or fatal respiratory depression may occur. Monitor patients closely, especially during initiation or following a dose increase. 4. **Accidental Ingestion:** Accidental ingestion of tramadol/paracetamol, especially by children, can result in a fatal overdose. 5. **Neonatal Opioid Withdrawal Syndrome:** Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. 6. **CYP2D6 Ultra-Rapid Metabolizers:** Life-threatening respiratory depression and death have occurred in children who received tramadol and became ultra-rapid metabolizers of tramadol due to a CYP2D6 polymorphism. Tramadol/paracetamol is contraindicated in children younger than 12 years of age and in adolescents younger than 18 years of age following tonsillectomy and/or adenoidectomy. Avoid use in adolescents 12 to 18 years of age who have other risk factors for respiratory depression unless the benefits outweigh the risks.
- Use of tramadol/paracetamol requires careful consideration due to several significant risks.
- Serotonin Syndrome: The risk of serotonin syndrome, a potentially life-threatening condition, is increased with concomitant use of serotonergic drugs (e.
- g.
- , SSRIs, SNRIs, tricyclic antidepressants, triptans).
- Seizure Risk: Tramadol lowers the seizure threshold; patients with a history of epilepsy or those at risk of seizures should be closely monitored.
- Respiratory Depression: While less common than with full opioid agonists, respiratory depression can occur, particularly with higher doses or in patients with respiratory compromise.
- Hepatotoxicity: Due to the paracetamol component, acute liver failure can occur, often associated with cumulative doses exceeding recommended limits.
- Risks are amplified in patients with pre-existing liver disease or those consuming alcohol.
- Adrenal Insufficiency: Opioid use may cause adrenal insufficiency, requiring corticosteroid supplementation.
- Hypoglycemia: Cases of hypoglycemia, sometimes severe, have been reported.
- Increased Intracranial Pressure: Opioids can elevate CSF pressure and should be used with caution in patients with head injuries or pre-existing elevated intracranial pressure.
- Withdrawal Symptoms: Abrupt discontinuation after prolonged use can lead to opioid withdrawal symptoms.
How it Works (Mechanism of Action)
The analgesic action of this combination product is multifactorial, leveraging distinct mechanisms from its two active components. Tramadol is a centrally acting synthetic opioid analgesic. Its primary mechanisms involve binding to mu-opioid receptors, which inhibits pain signal transmission. Additionally, tramadol weakly inhibits the reuptake of norepinephrine and serotonin, thereby enhancing descending pain inhibitory pathways in the central nervous system. These non-opioid mechanisms contribute to its analgesic profile. Paracetamol (acetaminophen) exerts its analgesic effects primarily through central mechanisms, though its precise molecular target is not fully elucidated. It is thought to inhibit prostaglandin synthesis in the central nervous system, reducing the sensation of pain, and may also involve modulation of the serotonergic system or nitric oxide pathways. The combination of tramadol and paracetamol provides an additive or synergistic analgesic effect, allowing for effective pain relief with potentially lower doses of each component compared to monotherapy, thereby potentially reducing individual drug-specific side effects.